Of significance and supporting a potential anti-cancer action of metformin is that LKB1 is a tumor suppressor and that mutations in LKB1 are observed in numerous cancers that result in the reduction of the inhibitory effect of the LKB1/AMPK pathway on the pro-proliferative signaling via mTOR (125, 126). Here, STK11 is linked to cancer.